ADNI4
Alzheimer's Disease Neuroimaging Initiative 4 Protocol
Purpose
The ADNI4 (Alzheimer's Disease Neuroimaging Initiative 4) Protocol is the fifth wave of a North American multicenter observational study launched in 2004, sponsored by the National Institute on Aging and the National Institutes of Health. The primary goal of this study is to discover, optimize, standardize, and validate clinical biomarkers used in Alzheimer's disease research and clinical trials. This study seeks to enroll individuals ages 55-90, willing and able to undergo yearly test procedures including cognitive tests, questionnaires, brain imaging, blood draws, and spinal taps. Eligible individuals may have normal cognition with no memory concerns, or have memory concerns and diagnosis of mild cognitive impairment or dementia due to Alzheimer’s disease. Participants will be evaluated on a yearly basis, for 2 to 4 years.
(PI: Maryam Beigi, MD, Easton Center's Katherine and Benjamin Kagan Alzheimer's Disease Treatment Development Program)
Contact: Kagan Clinical Trials Program at (310) 794-6191 or send an email to EastonClinicalTrials@mednet.ucla.edu to participate in this study or for more information.
Sponsor: University of Southern California
ClinicalTrials.gov Identifier: NCT05617014
Condition:
Mild Cognitive Impairment (MCI)
Alzheimer's Disease (AD)
Study Type: Observational
Study Design:
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) Protocol
Length of Study: Participants will be evaluated on a yearly basis, for 2 to 4 years.
Source: ClinicalTrials.gov
Ages Eligible for Study: 55 Years to 90 Years
Genders Eligible for Study: Both